Search Result

Isoforms Recommended:	PI3Kα

Results for "

p110α

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (6) Autophagy (5) Casein Kinase (1) DNA-PK (5) Influenza Virus (1) mTOR (6) PI3K (26) PIKfyve (1)
By Research Areas:	Cancer (25) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (2) Metabolic Disease (2)

Inhibitors & Agonists

Screening Libraries

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13281

PIK-75 hydrochloride 3 Publications Verification	DNA-PK PI3K Apoptosis	Cancer
PIK-75 hydrochloride is a reversible DNA-PK and *p110α*-selective inhibitor, which inhibits DNA-PK, *p110α* and p110γ with IC₅₀s of 2, 5.8 and 76 nM, respectively. PIK-75 hydrochloride inhibits p110α >200-fold more potently than p110β (IC₅₀=1.3 μM) . PIK-75 hydrochloride induces apoptosis .

HY-139412

Gilmelisib

PI3K Cancer

Gilmelisib is an antineoplastic. Gilmelisib is a PI3K inhibitor (IC₅₀ <1 nM for PI3K p110α) extracted from WO2017101847 A1, compound 1 .
HY-12285

Serabelisib

MLN1117; INK1117; TAK-117
PI3K Cancer

Serabelisib (MLN1117) is a selective p110α inhibitor with an IC₅₀ of 15 nM.

Gilmelisib	PI3K	Cancer
Gilmelisib is an antineoplastic. Gilmelisib is a PI3K inhibitor (IC₅₀ <1 nM for PI3K p110α) extracted from WO2017101847 A1, compound 1 .

Serabelisib MLN1117; INK1117; TAK-117	PI3K	Cancer
Serabelisib (MLN1117) is a selective *p110α* inhibitor with an IC₅₀ of 15 nM.

HY-107834

PIK-75	DNA-PK PI3K Apoptosis	Cancer
PIK-75 is a reversible DNA-PK and *p110α*-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC₅₀s of 2, 5.8 and 76 nM, respectively. PIK-75 inhibits p110α >200-fold more potently than p110β (IC₅₀=1.3 μM) . PIK-75 induces apoptosis .

HY-103030

PI3K-IN-32

PI3K Cancer

PI3K-IN-32 (compound 35) is a potent PI3K p110α inhibitor with an pIC₅₀ of 6.85 .
HY-13261

A66

4 Publications Verification

PI3K Cancer

A66 is a highly specific and selective p110α inhibitor with an IC₅₀ of 32 nM.

PI3K-IN-32	PI3K	Cancer
PI3K-IN-32 (compound 35) is a potent PI3K p110α inhibitor with an pIC₅₀ of 6.85 .

A66 4 Publications Verification	PI3K	Cancer
A66 is a highly specific and selective *p110α* inhibitor with an IC₅₀ of 32 nM.

HY-157287

(S)-Phe-A110/B319	Others	Inflammation/Immunology
(S)-Phe-A110/B319 is a selective binde that has 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α PI3K complex .

HY-12030

PIK-90

2 Publications Verification

PI3K DNA-PK Cancer

PIK-90 is a DNA-PK and PI3K inhibitor, which inhibits p110α, p110γ and DNA-PK with IC₅₀s of 11, 18 and 13 nM, respectively.

PIK-90 2 Publications Verification	PI3K DNA-PK	Cancer
PIK-90 is a DNA-PK and PI3K inhibitor, which inhibits *p110α, p110γ* and DNA-PK with IC₅₀s of 11, 18 and 13 nM, respectively.

HY-13228

YM-201636 10+ Cited Publications	PIKfyve PI3K Autophagy Influenza Virus	Infection Cancer
YM-201636 is a potent and selective PIKfyve inhibitor with an IC₅₀ of 33 nM. YM-201636 also inhibits p110α with an IC₅₀ of 3.3 μM. YM-201636 inhibits retroviral replication.

HY-17044

Duvelisib 5+ Cited Publications IPI-145; INK1197	PI3K	Cancer
Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC₅₀ of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively .

HY-157288

(R)-Phe-A110/B319	Others	Metabolic Disease
(R)-Phe-A110/B319, a hapten, is a selective binder to tumor-associated antigens. (R)-Phe-A110/B319 has a 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α PI3K complex. (R)-Phe-A110/B319 can be used for the research of conditional chimeric antigen receptor T (CAR-T) cell activation and tumor targeting .

HY-15244

Alpelisib 75+ Cited Publications BYL-719	PI3K	Cancer
Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC₅₀s of 5/250/290/1200 nM, respectively. Antineoplastic activity .

HY-70063

Buparlisib 55+ Cited Publications BKM120; NVP-BKM120	PI3K Apoptosis	Cancer
Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC₅₀s of 52, 166, 116 and 262 nM for *p110α, p110β, p110δ* and *p110γ*, respectively.

HY-108606

PI-828 1 Publications Verification	PI3K Casein Kinase	Cancer
PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with IC₅₀s of 173 nM, 149 nM, and 1127 nM for *p110α, CK2, and CK2α2* in lipid kinase assay, respectively .

HY-13504

PIK-293 1 Publications Verification	PI3K	Metabolic Disease Cancer
PIK-293, an analog of IC87114, is a PI3K inhibitor, with IC₅₀ values of 0.24 μM, 10 μM, 25 μM and 100 μM for p110δ, p110β, p110γ and p110α, respectively .

HY-100706

AMA-37
AMA-37, an Arylmorpholine analog, is ATP-competitive DNA-PK inhibitor, with IC₅₀ values of 0.27 μM (DNA-PK), 32 μM (p110α), 3.7 μM (p110β), and 22 μM (p110γ), respectively .

HY-15245

GSK2636771 5+ Cited Publications	PI3K	Cancer
GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a K_i of 0.89 nM and an IC₅₀ of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.

HY-N6775

Sonolisib 1 Publications Verification PX-866	PI3K	Cancer
Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of PI3K (IC₅₀=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). Antitumor activity .

HY-163360

PI3Kα-IN-19	PI3K	Cancer
PI3Kα-IN-19 (Compound 1) is a PI3Kα inhibitor with a targeted binding site at the *p110α* catalytic subunit. PI3Kα is one of the most common dysregulated kinases used in cancer research .

HY-12235

PI-3065 3 Publications Verification	PI3K	Inflammation/Immunology Cancer
PI-3065 is a potent inhibitor of PI3K p110δ, with IC₅₀ and K_i values of 5 nM and 1.5 nM, and exhibits less potent activity against p110α, p110β, p110γ with IC₅₀s of 910, 600, >10000 nM.

HY-15180

Buparlisib Hydrochloride 55+ Cited Publications BKM120 Hydrochloride; NVP-BKM120 Hydrochloride	PI3K Apoptosis	Cancer
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I PI3K inhibitor, with IC₅₀ of 52 nM/166 nM/116 nM/262 nM for *p110α/p110β/p110δ/p110γ*, respectively.

HY-15244A

Alpelisib hydrochloride BYL-719 hydrochloride	PI3K	Cancer
Alpelisib hydrochloride (BYL-719 hydrochloride) is a potent, orally active, and selective PI3Kα inhibitor with IC₅₀s of 5 nM, 250 nM, 290 nM and 1200 nM for *p110α, p110γ, p110δ, and p110β*, respectively. Alpelisib hydrochloride (BYL-719 hydrochloride) shows antineoplastic activity .

HY-10108A

LY294002 hydrochloride
LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC₅₀ values of 0.5, 0.57, and 0.97 μM for *P110α, P110δ* and *P110β, respectively. LY294002 hydrochloride also inhibits CK2* with an IC₅₀ of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .

HY-156371

MIPS-21335	PI3K	Cardiovascular Disease
MIPS-21335 is an PI3KC2α inhibitor (IC₅₀: 7 nM). MIPS-21335 also inhibits PI3KC2β, p110α, p110β and p110δ (IC₅₀: 0.043, 0.140, 0.386, 0.742 μM). MIPS-21335 has antithrombotic effect .

HY-10297

Omipalisib 10+ Cited Publications GSK2126458; GSK458	PI3K mTOR Autophagy	Cancer
Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with K_is of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity .

HY-10115

PI-103 15+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 is a potent PI3K and mTOR inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for *p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 induces autophagy .

HY-10115A

PI-103 Hydrochloride 15+ Cited Publications	PI3K mTOR DNA-PK Autophagy Apoptosis	Cancer
PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC₅₀s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for *p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK* with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .

HY-50673

Dactolisib 45+ Cited Publications BEZ235; NVP-BEZ235	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC₅₀s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for *p110α/p110γ/p110δ/p110β* and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.

HY-15900

Voxtalisib 4 Publications Verification XL765; SAR245409	PI3K mTOR	Cancer
Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC₅₀s=39, 113, 9 and 43 nM for *p110α, p110β, p110γ* and *p110δ, respectively), also inhibits DNA-PK (IC₅₀=150 nM) and mTOR (IC₅₀=157 nM). Voxtalisib (XL765) inhibits mTORC1* and mTORC2 with IC₅₀s of 160 and 910 nM, respectively.

HY-10116

PI-540	PI3K mTOR	Cancer
PI-540 is a bicyclic thienopyrimidine derivative and an orally active PI3K inhibitor. PI-540 has anti-cancer cell proliferation properties and high tissue distribution. PI-540 can inhibit different isoforms of PI3K, with IC₅₀s of 10 nM (P110α), 3510 nM (P110β), 410 nM (P110δ), and 33110 nM (P110γ). PI-540 also inhibits mTOR (IC₅₀: 61 nM) and DNA-PK (IC₅₀: 525 nM) .

PI3K/Akt/mTOR Compound Library	558 compounds
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials. MCE owns a unique collection of 558 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

PIK3CA Antibody PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; PIK3C A; PK3CA; PtdIns 3 kinase p110; PI3-kinase p110α; PI3-kinase p110 subunit alpha; PI 3 Kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase p110α.	WB; ELISA; IHC-P; IHC-F; ICC; IF	Human, Mouse, Rat(predicted: Chicken, Cow, Rabbit)
PIK3CA Antibody is an unconjugated, approximately 117 kDa, rabbit-derived, anti-PIK3CA polyclonal antibody. PIK3CA Antibody can be used for: WB, ELISA, IHC-P, IHC-F, ICC, IF expriments in human, mouse, rat, and predicted: chicken, cow, rabbit background without labeling.

phospho-PI3KCA (Tyr317) Antibody PIK3CA(phospho Y317); PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; PIK3C A; PIK3CA; PK3CA; PtdIns 3 kinase p110; PI3-kinase p110α; PI3-kinase p110 subunit alpha; PI 3 Kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase p110α.	WB; ELISA; IHC-P; IHC-F; IF	Human, Mouse(predicted: Rat)
phospho-PI3KCA (Tyr317) Antibody is an unconjugated, approximately 117 kDa, rabbit-derived, anti-phospho-PI3KCA (Tyr317) polyclonal antibody. phospho-PI3KCA (Tyr317) Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat background without labeling.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: